Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

NCT ID: NCT00621686

Last Updated: 2018-05-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-09-30
• Study Completion Date: 2014-02-19

Brief Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving bevacizumab together with sorafenib may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects and how well giving bevacizumab together with sorafenib works in treating patients with recurrent glioblastoma multiforme.

Detailed Description

OBJECTIVES:

Primary

• Identify the clinical efficacy of bevacizumab and sorafenib, as measured by 6-month progression-free survival, in patients with recurrent glioblastoma multiforme.

Secondary

• Assess time to progression of this patient population.
• Assess overall survival of this patient population.

OUTLINE: This is a multicenter study.

Patients receive oral sorafenib once daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.

Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.

After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years.

Conditions

Brain and Central Nervous System Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sorafenib + Bevacizumab/Group A

Patients receive oral sorafenib 400 mg (200 mg twice daily) days 1-5 and 8-12 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.

Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.

Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.

After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years.

Group Type: EXPERIMENTAL

bevacizumab

Intervention Type: BIOLOGICAL

sorafenib tosylate

Intervention Type: DRUG

Sorafenib + Bevacizumab /Group B

Patients receive oral sorafenib 200 mg once daily on days 1-14 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.

Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.

Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.

After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years.

Group Type: EXPERIMENTAL

bevacizumab

Intervention Type: BIOLOGICAL

sorafenib tosylate

Intervention Type: DRUG

Interventions

bevacizumab

Intervention Type: BIOLOGICAL

sorafenib tosylate

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with old blood products or hemosiderin without a history of spontaneous bleeding are eligible

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin > 9.0 g/dL
• Total bilirubin ≤ 1.5 times upper limit of normal
• AST ≤ 3 times upper limit of normal
• Creatinine ≤ upper limit of normal
• Urine protein:creatinine ratio < 1 OR urine protein < 1,000 mg by 24-hour urine collection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for six months after completion of study treatment
• Able to complete questionnaire(s) alone or with assistance
• Willing to return to NCCTG enrolling institution for follow-up
• Willing to provide mandatory blood samples for research purposes
• Not immunocompromised (other than that related to the use of corticosteroids)
• No known HIV positivity
• No concurrent uncontrolled illness including, but not limited to, the following:

• Ongoing or active infection
• Symptomatic congestive heart failure
• Unstable angina pectoris
• Cardiac arrhythmia
• Psychiatric illness/social situations that would limit compliance with study requirements
• No inadequately controlled hypertension (i.e., systolic blood pressure [BP] > 150 mm Hg or diastolic BP > 100 mm Hg while on antihypertensive medications)

• Patients with well-controlled hypertension are eligible
• No myocardial infarction or unstable angina within the past 6 months
• No congestive heart failure requiring the use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
• No New York Heart Association class II-IV congestive heart failure
• No significant vascular disease (e.g., aortic aneurysm or aortic dissection)
• No peripheral arterial thrombosis within the past 6 months
• No stroke or transient ischemic attack within the past 6 months
• No history of hypertensive crisis or hypertensive encephalopathy
• No evidence of bleeding diathesis (greater than normal risk of bleeding) or coagulopathy (in the absence of therapeutic anticoagulation)
• No active or recent history of hemoptysis (i.e., ≥ ½ teaspoon of bright red blood per episode) within the past 30 days
• No serious, nonhealing wounds, ulcers, or bone fractures
• No condition that impairs the ability to swallow pills (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation)
• No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
• No significant traumatic injury within the past 28 days
• No known hypersensitivity to any of the components of sorafenib or bevacizumab
• No other active malignancy within the past 3 years, except nonmelanoma skin cancer or carcinoma in situ of the cervix

• Patients with a history of prior malignancy must not be receiving specific treatment (other than hormonal therapy) for that malignancy
• No co-morbid systemic illness or other concurrent severe disease that, in the judgment of the investigator, would make the patient inappropriate for entry into this study or significantly interfere with the proper assessment of safety and toxicity of the prescribed study regimen

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• At least 12 weeks since prior radiotherapy
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
• More than 2 weeks since prior small molecule cell cycle inhibitors
• At least 1 week since prior fixed-dose corticosteroids (or no corticosteroids)
• No prior intratumoral chemotherapy, stereotactic radiosurgery or interstitial brachytherapy unless there is a separate lesion on MRI that is not part of the prior treatment field OR there is proof of recurrent disease based on biopsy, MRI spectroscopy, or PET scan
• No prior antiangiogenic therapy
• No prior surgical procedures affecting absorption
• More than 7 days since prior core biopsy or other minor surgical procedures

• Placement of a vascular access device is allowed
• More than 28 days since prior major surgical procedure or open biopsy
• No concurrent major surgical procedure
• No other concurrent investigational agents
• No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, fosphenytoin, carbamazepine, phenobarbital, or primidone)
• No other concurrent potent CYP3A4 inducers (e.g., rifampin or St. John's wort)
• No concurrent therapeutic anticoagulation with warfarin

• Prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial access devices allowed provided the INR < 1.5
• Therapeutic anticoagulation with low molecular weight heparin allowed

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Alliance for Clinical Trials in Oncology

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Evanthia Galanis, MD

Role: STUDY_CHAIR

Mayo Clinic

Locations

Mayo Clinic Scottsdale

Scottsdale, Arizona, United States

Cancer Care Associates

Fresno, California, United States

Front Range Cancer Specialists

Fort Collins, Colorado, United States

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

Hartford, Connecticut, United States

Baptist Cancer Institute - Jacksonville

Jacksonville, Florida, United States

Mayo Clinic - Jacksonville

Jacksonville, Florida, United States

Rush-Copley Cancer Care Center

Aurora, Illinois, United States

Carle Cancer Center at Carle Foundation Hospital

Urbana, Illinois, United States

CCOP - Carle Cancer Center

Urbana, Illinois, United States

St. Francis Hospital and Health Centers - Beech Grove Campus

Beech Grove, Indiana, United States

Reid Hospital & Health Care Services

Richmond, Indiana, United States

McFarland Clinic, PC

Ames, Iowa, United States

Cedar Rapids Oncology Associates

Cedar Rapids, Iowa, United States

Mercy Regional Cancer Center at Mercy Medical Center

Cedar Rapids, Iowa, United States

Medical Oncology and Hematology Associates - West Des Moines

Clive, Iowa, United States

Mercy Capitol Hospital

Des Moines, Iowa, United States

CCOP - Iowa Oncology Research Association

Des Moines, Iowa, United States

John Stoddard Cancer Center at Iowa Methodist Medical Center

Des Moines, Iowa, United States

Medical Oncology and Hematology Associates at John Stoddard Cancer Center

Des Moines, Iowa, United States

Medical Oncology and Hematology Associates at Mercy Cancer Center

Des Moines, Iowa, United States

Mercy Cancer Center at Mercy Medical Center - Des Moines

Des Moines, Iowa, United States

John Stoddard Cancer Center at Iowa Lutheran Hospital

Des Moines, Iowa, United States

McCreery Cancer Center at Ottumwa Regional

Ottumwa, Iowa, United States

Siouxland Hematology-Oncology Associates, LLP

Sioux City, Iowa, United States

Mercy Medical Center - Sioux City

Sioux City, Iowa, United States

St. Luke's Regional Medical Center

Sioux City, Iowa, United States

Cancer Center of Kansas, PA - Chanute

Chanute, Kansas, United States

Cancer Center of Kansas, PA - Dodge City

Dodge City, Kansas, United States

Cancer Center of Kansas, PA - El Dorado

El Dorado, Kansas, United States

Cancer Center of Kansas - Fort Scott

Fort Scott, Kansas, United States

Cancer Center of Kansas-Independence

Independence, Kansas, United States

Cancer Center of Kansas, PA - Kingman

Kingman, Kansas, United States

Lawrence Memorial Hospital

Lawrence, Kansas, United States

Southwest Medical Center

Liberal, Kansas, United States

Cancer Center of Kansas, PA - Newton

Newton, Kansas, United States

Cancer Center of Kansas, PA - Parsons

Parsons, Kansas, United States

Cancer Center of Kansas, PA - Pratt

Pratt, Kansas, United States

Cancer Center of Kansas, PA - Salina

Salina, Kansas, United States

Cancer Center of Kansas, PA - Wellington

Wellington, Kansas, United States

Associates in Womens Health, PA - North Review

Wichita, Kansas, United States

Cancer Center of Kansas, PA - Medical Arts Tower

Wichita, Kansas, United States

Cancer Center of Kansas, PA - Wichita

Wichita, Kansas, United States

CCOP - Wichita

Wichita, Kansas, United States

Via Christi Cancer Center at Via Christi Regional Medical Center

Wichita, Kansas, United States

Cancer Center of Kansas, PA - Winfield

Winfield, Kansas, United States

Drs. Carrol, Sheth, Raghavan

Louisville, Kentucky, United States

Hickman Cancer Center at Bixby Medical Center

Adrian, Michigan, United States

Saint Joseph Mercy Cancer Center

Ann Arbor, Michigan, United States

CCOP - Michigan Cancer Research Consortium

Ann Arbor, Michigan, United States

Oakwood Cancer Center at Oakwood Hospital and Medical Center

Dearborn, Michigan, United States

Green Bay Oncology, Limited - Escanaba

Escanaba, Michigan, United States

Genesys Hurley Cancer Institute

Flint, Michigan, United States

Hurley Medical Center

Flint, Michigan, United States

Van Elslander Cancer Center at St. John Hospital and Medical Center

Grosse Pointe Woods, Michigan, United States

Dickinson County Healthcare System

Iron Mountain, Michigan, United States

Foote Memorial Hospital

Jackson, Michigan, United States

Haematology-Oncology Associates of Ohio and Michigan, PC

Lambertville, Michigan, United States

Sparrow Regional Cancer Center

Lansing, Michigan, United States

St. Mary Mercy Hospital

Livonia, Michigan, United States

Community Cancer Center of Monroe

Monroe, Michigan, United States

Mercy Memorial Hospital - Monroe

Monroe, Michigan, United States

St. Joseph Mercy Oakland

Pontiac, Michigan, United States

Mercy Regional Cancer Center at Mercy Hospital

Port Huron, Michigan, United States

Seton Cancer Institute at Saint Mary's - Saginaw

Saginaw, Michigan, United States

St. John Macomb Hospital

Warren, Michigan, United States

Alexandria, Minnesota, United States

MeritCare Bemidji

Bemidji, Minnesota, United States

Fairview Ridges Hospital

Burnsville, Minnesota, United States

Mercy and Unity Cancer Center at Mercy Hospital

Coon Rapids, Minnesota, United States

Duluth Clinic Cancer Center - Duluth

Duluth, Minnesota, United States

CCOP - Duluth

Duluth, Minnesota, United States

Miller - Dwan Medical Center

Duluth, Minnesota, United States

Fairview Southdale Hospital

Edina, Minnesota, United States

Fergus Falls Medical Group, PA

Fergus Falls, Minnesota, United States

Mercy and Unity Cancer Center at Unity Hospital

Fridley, Minnesota, United States

Hutchinson Area Health Care

Hutchinson, Minnesota, United States

HealthEast Cancer Care at St. John's Hospital

Maplewood, Minnesota, United States

Minnesota Oncology Hematology, PA - Maplewood

Maplewood, Minnesota, United States

Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

Minneapolis, Minnesota, United States

Hennepin County Medical Center - Minneapolis

Minneapolis, Minnesota, United States

Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center

Robbinsdale, Minnesota, United States

Mayo Clinic Cancer Center

Rochester, Minnesota, United States

CentraCare Clinic - River Campus

Saint Cloud, Minnesota, United States

Coborn Cancer Center

Saint Cloud, Minnesota, United States

CCOP - Metro-Minnesota

Saint Louis Park, Minnesota, United States

Park Nicollet Cancer Center

Saint Louis Park, Minnesota, United States

Regions Hospital Cancer Care Center

Saint Paul, Minnesota, United States

United Hospital

Saint Paul, Minnesota, United States

St. Francis Cancer Center at St. Francis Medical Center

Shakopee, Minnesota, United States

Ridgeview Medical Center

Waconia, Minnesota, United States

Minnesota Oncology Hematology, PA - Woodbury

Woodbury, Minnesota, United States

CCOP - Cancer Research for the Ozarks

Springfield, Missouri, United States

St. John's Regional Health Center

Springfield, Missouri, United States

Hulston Cancer Center at Cox Medical Center South

Springfield, Missouri, United States

CCOP - Montana Cancer Consortium

Billings, Montana, United States

Hematology-Oncology Centers of the Northern Rockies - Billings

Billings, Montana, United States

Northern Rockies Radiation Oncology Center

Billings, Montana, United States

St. Vincent Healthcare Cancer Care Services

Billings, Montana, United States

Billings Clinic - Downtown

Billings, Montana, United States

Bozeman Deaconess Cancer Center

Bozeman, Montana, United States

St. James Healthcare Cancer Care

Butte, Montana, United States

Great Falls Clinic - Main Facility

Great Falls, Montana, United States

Great Falls, Montana, United States

Northern Montana Hospital

Havre, Montana, United States

St. Peter's Hospital

Helena, Montana, United States

Glacier Oncology, PLLC

Kalispell, Montana, United States

Kalispell Medical Oncology at KRMC

Kalispell, Montana, United States

Kalispell Regional Medical Center

Kalispell, Montana, United States

Community Medical Center

Missoula, Montana, United States

Guardian Oncology and Center for Wellness

Missoula, Montana, United States

Montana Cancer Specialists at Montana Cancer Center

Missoula, Montana, United States

Montana Cancer Center at St. Patrick Hospital and Health Sciences Center

Missoula, Montana, United States

Cancer Resource Center - Lincoln

Lincoln, Nebraska, United States

CCOP - Missouri Valley Cancer Consortium

Omaha, Nebraska, United States

Immanuel Medical Center

Omaha, Nebraska, United States

Alegant Health Cancer Center at Bergan Mercy Medical Center

Omaha, Nebraska, United States

Creighton University Medical Center

Omaha, Nebraska, United States

Rutherford Hospital

Rutherfordton, North Carolina, United States

Bismarck Cancer Center

Bismarck, North Dakota, United States

Medcenter One Hospital Cancer Care Center

Bismarck, North Dakota, United States

Mid Dakota Clinic, PC

Bismarck, North Dakota, United States

St. Alexius Medical Center Cancer Center

Bismarck, North Dakota, United States

CCOP - MeritCare Hospital

Fargo, North Dakota, United States

MeritCare Broadway

Fargo, North Dakota, United States

Mary Rutan Hospital

Bellefontaine, Ohio, United States

Wood County Oncology Center

Bowling Green, Ohio, United States

Adena Regional Medical Center

Chillicothe, Ohio, United States

Charles M. Barrett Cancer Center at University Hospital

Cincinnati, Ohio, United States

North Coast Cancer Care - Clyde

Clyde, Ohio, United States

Riverside Methodist Hospital Cancer Care

Columbus, Ohio, United States

CCOP - Columbus

Columbus, Ohio, United States

Grant Medical Center Cancer Care

Columbus, Ohio, United States

Mount Carmel Health - West Hospital

Columbus, Ohio, United States

Doctors Hospital at Ohio Health

Columbus, Ohio, United States

Grandview Hospital

Dayton, Ohio, United States

Good Samaritan Hospital

Dayton, Ohio, United States

David L. Rike Cancer Center at Miami Valley Hospital

Dayton, Ohio, United States

Samaritan North Cancer Care Center

Dayton, Ohio, United States

CCOP - Dayton

Dayton, Ohio, United States

Grady Memorial Hospital

Delaware, Ohio, United States

Hematology Oncology Center

Elyria, Ohio, United States

Blanchard Valley Medical Associates

Findlay, Ohio, United States

Middletown Regional Hospital

Franklin, Ohio, United States

Wayne Hospital

Greenville, Ohio, United States

Charles F. Kettering Memorial Hospital

Kettering, Ohio, United States

Fairfield Medical Center

Lancaster, Ohio, United States

Lima Memorial Hospital

Lima, Ohio, United States

Strecker Cancer Center at Marietta Memorial Hospital

Marietta, Ohio, United States

Northwest Ohio Oncology Center

Maumee, Ohio, United States

St. Luke's Hospital

Maumee, Ohio, United States

Licking Memorial Cancer Care Program at Licking Memorial Hospital

Newark, Ohio, United States

Fisher-Titus Medical Center

Norwalk, Ohio, United States

St. Charles Mercy Hospital

Oregon, Ohio, United States

Toledo Clinic - Oregon

Oregon, Ohio, United States

North Coast Cancer Care, Incorporated

Sandusky, Ohio, United States

Mercy Medical Center

Springfield, Ohio, United States

Community Hospital of Springfield and Clark County

Springfield, Ohio, United States

Flower Hospital Cancer Center

Sylvania, Ohio, United States

Mercy Hospital of Tiffin

Tiffin, Ohio, United States

Toledo Hospital

Toledo, Ohio, United States

St. Vincent Mercy Medical Center

Toledo, Ohio, United States

Medical University of Ohio Cancer Center

Toledo, Ohio, United States

CCOP - Toledo Community Hospital

Toledo, Ohio, United States

St. Anne Mercy Hospital

Toledo, Ohio, United States

Toledo Clinic, Incorporated - Main Clinic

Toledo, Ohio, United States

UVMC Cancer Care Center at Upper Valley Medical Center

Troy, Ohio, United States

Fulton County Health Center

Wauseon, Ohio, United States

Precision Radiotherapy at University Pointe

West Chester, Ohio, United States

Mount Carmel St. Ann's Cancer Center

Westerville, Ohio, United States

Clinton Memorial Hospital

Wilmington, Ohio, United States

Ruth G. McMillan Cancer Center at Greene Memorial Hospital

Xenia, Ohio, United States

Genesis - Good Samaritan Hospital

Zanesville, Ohio, United States

Providence Milwaukie Hospital

Milwaukie, Oregon, United States

Legacy Good Samaritan Hospital & Comprehensive Cancer Center

Portland, Oregon, United States

Providence Cancer Center at Providence Portland Medical Center

Portland, Oregon, United States

Adventist Medical Center

Portland, Oregon, United States

CCOP - Columbia River Oncology Program

Portland, Oregon, United States

Providence St. Vincent Medical Center

Portland, Oregon, United States

Northwest Cancer Specialists at Rose Quarter Cancer Center

Portland, Oregon, United States

Knight Cancer Institute at Oregon Health and Science University

Portland, Oregon, United States

Geisinger Cancer Institute at Geisinger Health

Danville, Pennsylvania, United States

Geisinger Hazleton Cancer Center

Hazleton, Pennsylvania, United States

Geisinger Medical Group - Scenery Park

State College, Pennsylvania, United States

Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center

Wilkes-Barre, Pennsylvania, United States

AnMed Cancer Center

Anderson, South Carolina, United States

CCOP - Upstate Carolina

Spartanburg, South Carolina, United States

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

Spartanburg, South Carolina, United States

Rapid City Regional Hospital

Rapid City, South Dakota, United States

Medical X-Ray Center, PC

Sioux Falls, South Dakota, United States

Sanford Cancer Center at Sanford USD Medical Center

Sioux Falls, South Dakota, United States

Fredericksburg Oncology, Incorporated

Fredericksburg, Virginia, United States

Southwest Washington Medical Center Cancer Center

Vancouver, Washington, United States

Luther Midlelfort Hospital

Eau Claire, Wisconsin, United States

Midelfort Clinic - Luther

Eau Claire, Wisconsin, United States

Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center

Green Bay, Wisconsin, United States

Green Bay Oncology, Limited at St. Mary's Hospital

Green Bay, Wisconsin, United States

St. Mary's Hospital Medical Center - Green Bay

Green Bay, Wisconsin, United States

St. Vincent Hospital Regional Cancer Center

Green Bay, Wisconsin, United States

Holy Family Memorial Medical Center Cancer Care Center

Manitowoc, Wisconsin, United States

Bay Area Cancer Care Center at Bay Area Medical Center

Marinette, Wisconsin, United States

Green Bay Oncology, Limited - Oconto Falls

Oconto Falls, Wisconsin, United States

Green Bay Oncology, Limited - Sturgeon Bay

Sturgeon Bay, Wisconsin, United States

Rocky Mountain Oncology

Casper, Wyoming, United States

Welch Cancer Center at Sheridan Memorial Hospital

Sheridan, Wyoming, United States

Countries

United States

References

Galanis E, Jaeckle KA, Anderson S, et al.: NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. [Abstract] J Clin Oncol 28 (Suppl 15): A-2018, 2010.

Reference Type: RESULT

Other Identifiers

NCI-2009-00832

Identifier Type: REGISTRY

Identifier Source: secondary_id

CDR0000587614

Identifier Type: REGISTRY

Identifier Source: secondary_id

NCCTG-N0776

Identifier Type: -

Identifier Source: org_study_id